{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T05:44:23Z","timestamp":1767851063032,"version":"3.49.0"},"reference-count":39,"publisher":"American Society for Microbiology","issue":"11","license":[{"start":{"date-parts":[[2014,11,1]],"date-time":"2014-11-01T00:00:00Z","timestamp":1414800000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2014,11]]},"abstract":"<jats:title>ABSTRACT<\/jats:title><jats:p>Concomitant treatment of tuberculosis (TB) and HIV is recommended and improves outcomes. Bedaquiline is a novel drug for the treatment of multidrug-resistant (MDR) TB; combined use with antiretroviral drugs, nevirapine, or ritonavir-boosted lopinavir (LPV\/r) is anticipated, but no clinical data from coinfected patients are available. Plasma concentrations of bedaquiline and its M2 metabolite after single doses were obtained from interaction studies with nevirapine or LPV\/r in healthy volunteers. The antiretrovirals' effects on bedaquiline and M2 pharmacokinetics were assessed by nonlinear mixed-effects modeling. Potential dose adjustments were evaluated with simulations. No significant effects of nevirapine on bedaquiline pharmacokinetics were identified. LPV\/r decreased bedaquiline and M2 clearances to 35% (relative standard error [RSE], 9.2%) and 58% (RSE, 8.4%), respectively, of those without comedication. As almost 3-fold (bedaquiline) and 2-fold (M2) increases in exposures during chronic treatment with LPV\/r are expected, dose adjustments are suggested for evaluation. Efficacious, safe bedaquiline dosing for MDR-TB patients receiving antiretrovirals is important. Modeling results suggest that bedaquiline can be coadministered with nevirapine without dose adjustments. The predicted elevation of bedaquiline and M2 levels during LPV\/r coadministration may be a safety concern, and careful monitoring is recommended. Further data are being collected in coinfected patients to determine whether dose adjustments are needed. (These studies have been registered at ClinicalTrials.gov under registration numbers NCT00828529 [study C110] and NCT00910806 [study C117].)<\/jats:p>","DOI":"10.1128\/aac.03246-14","type":"journal-article","created":{"date-parts":[[2014,8,12]],"date-time":"2014-08-12T06:36:28Z","timestamp":1407825388000},"page":"6406-6412","update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":58,"title":["Impact of Lopinavir-Ritonavir or Nevirapine on Bedaquiline Exposures and Potential Implications for Patients with Tuberculosis-HIV Coinfection"],"prefix":"10.1128","volume":"58","author":[{"given":"Elin M.","family":"Svensson","sequence":"first","affiliation":[{"name":"Department of Pharmaceutical Biosciences, Uppsala University, Uppsala, Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kelly E.","family":"Dooley","sequence":"additional","affiliation":[{"name":"Johns Hopkins University School of Medicine, Baltimore, Maryland, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mats O.","family":"Karlsson","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Biosciences, Uppsala University, Uppsala, Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"235","reference":[{"key":"e_1_3_3_2_2","volume-title":"Global tuberculosis report","author":"World Health Organization","year":"2013","unstructured":"World Health Organization. 2013. Global tuberculosis report. World Health Organization, Geneva, Switzerland."},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0905848"},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1013911"},{"key":"e_1_3_3_5_2","volume-title":"WHO policy on collaborative TB\/HIV activities: guidelines for national programmes and other stakeholders","author":"World Health Organization","year":"2014","unstructured":"World Health Organization. 2014. WHO policy on collaborative TB\/HIV activities: guidelines for national programmes and other stakeholders. World Health Organization, Geneva, Switzerland."},{"key":"e_1_3_3_6_2","volume-title":"Anti-tuberculosis drug resistance in the world: fourth global report","author":"World Health Organization","year":"2014","unstructured":"World Health Organization. 2014. Anti-tuberculosis drug resistance in the world: fourth global report. World Health Organization, Geneva, Switzerland."},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(06)69573-1"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.1155\/2012\/874083"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.1106753"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.1038\/nchembio884"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.06126-11"},{"key":"e_1_3_3_12_2","volume-title":"Briefing package, NDA 204-384, Sirturo (bedaquiline 100 mg tablets), for the treatment of adults (\u226518 years) as part of combination therapy of pulmonary multi-drug resistant tuberculosis (MDRTB)","author":"FDA Office of Antimicrobial Products","year":"2014","unstructured":"FDA Office of Antimicrobial Products. 2014. Briefing package, NDA 204-384, Sirturo (bedaquiline 100 mg tablets), for the treatment of adults (\u226518 years) as part of combination therapy of pulmonary multi-drug resistant tuberculosis (MDRTB). Food and Drug Administration, Silver Spring, MD."},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1313865"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02243-12"},{"key":"e_1_3_3_15_2","volume-title":"Sirturo, United States product insert","author":"Janssen Pharmaceuticals","year":"2014","unstructured":"Janssen Pharmaceuticals. 2014. Sirturo, United States product insert. Janssen Pharmaceuticals, Beerse, Belgium. http:\/\/www.sirturo.com\/sites\/default\/files\/pdf\/sirturo-pi.pdf."},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.mjt.0000433951.09030.5a"},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dku171"},{"key":"e_1_3_3_18_2","volume-title":"Anti-Infective Drugs Advisory Committee meeting briefing document: TMC207 (bedaquiline): treatment of patients with MDR-TB","author":"Janssen Pharmaceuticals","year":"2014","unstructured":"Janssen Pharmaceuticals. 2014. Anti-Infective Drugs Advisory Committee meeting briefing document: TMC207 (bedaquiline): treatment of patients with MDR-TB. Janssen Pharmaceuticals, Beerse, Belgium. http:\/\/www.fda.gov\/downloads\/advisorycommittees\/committeesmeetingmaterials\/drugs\/anti-infectivedrugsadvisorycommittee\/ucm329260.pdf."},{"key":"e_1_3_3_19_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00191-13"},{"key":"e_1_3_3_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0009-9236(99)80079-4"},{"key":"e_1_3_3_21_2","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/S0022-3565(25)12840-1","article-title":"Cytochrome P450-mediated metabolism of the HIV-1 protease inhibitor ritonavir (ABT-538) in human liver microsomes","volume":"277","author":"Kumar GN","year":"1996","unstructured":"KumarGNRodriguesADBukoAMDenissenJF. 1996. Cytochrome P450-mediated metabolism of the HIV-1 protease inhibitor ritonavir (ABT-538) in human liver microsomes. J. Pharmacol. Exp. Ther. 277:423\u2013431.","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"e_1_3_3_22_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2125.1997.00644.x"},{"key":"e_1_3_3_23_2","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.30.7.795"},{"key":"e_1_3_3_24_2","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1046\/j.1365-2125.1998.00749.x","article-title":"Effect of ritonavir on the pharmacokinetics of ethinyl oestradiol in healthy female volunteers","volume":"46","author":"Ouellet D","year":"1998","unstructured":"OuelletDHsuAQianJLockeCSEasonCJCavanaughJHLeonardJMGrannemanGR. 1998. Effect of ritonavir on the pharmacokinetics of ethinyl oestradiol in healthy female volunteers. Br. J. Clin. Pharmacol. 46:111\u2013116.","journal-title":"Br. J. Clin. Pharmacol."},{"key":"e_1_3_3_25_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01418-13"},{"key":"e_1_3_3_26_2","doi-asserted-by":"publisher","DOI":"10.1208\/s12248-011-9255-z"},{"key":"e_1_3_3_27_2","volume-title":"NONMEM user's guides (1989\u20132012)","author":"Beal S","year":"2012","unstructured":"BealSSheinerLBBoeckmannABauerRJ. 2012. NONMEM user's guides (1989\u20132012). Icon Development Solutions, Ellicott City, MD."},{"key":"e_1_3_3_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmpb.2005.04.005"},{"key":"e_1_3_3_29_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0169-2607(98)00067-4"},{"key":"e_1_3_3_30_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmpb.2010.04.018"},{"key":"e_1_3_3_31_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-200342030-00002"},{"key":"e_1_3_3_32_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0009-9236(03)00006-7"},{"key":"e_1_3_3_33_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.tiv.2010.04.007"},{"key":"e_1_3_3_34_2","doi-asserted-by":"publisher","DOI":"10.1517\/14740338.5.4.567"},{"key":"e_1_3_3_35_2","volume-title":"The regulatory challenges of drug-induced phospholipidosis","author":"Food and Drug Administration","year":"2014","unstructured":"Food and Drug Administration. 2014. The regulatory challenges of drug-induced phospholipidosis. Food and Drug Administration, Silver Spring, MD. http:\/\/www.fda.gov\/downloads\/advisorycommittees\/committeesmeetingmaterials\/drugs\/advisorycommitteeforpharmaceuticalscienceandclinicalpharmacology\/ucm210798.pdf."},{"key":"e_1_3_3_36_2","doi-asserted-by":"publisher","DOI":"10.1590\/S1806-37132008001100009"},{"key":"e_1_3_3_37_2","doi-asserted-by":"crossref","first-page":"202","DOI":"10.7883\/yoken.JJID.2008.202","article-title":"Serum zinc and albumin levels in pulmonary tuberculosis patients with and without HIV","volume":"61","author":"Ramakrishnan K","year":"2008","unstructured":"RamakrishnanKShenbagarathaiRKavithaKUmaABalasubramaniamRThirumalaikolundusubramanianP. 2008. Serum zinc and albumin levels in pulmonary tuberculosis patients with and without HIV. Jpn. J. Infect. Dis. 61:202\u2013204.","journal-title":"Jpn. J. Infect. Dis."},{"key":"e_1_3_3_38_2","doi-asserted-by":"publisher","DOI":"10.1054\/tube.2002.0330"},{"key":"e_1_3_3_39_2","volume-title":"Proc. 38th World Conf. Lung Health","author":"Van Heeswijk R","year":"2007","unstructured":"Van HeeswijkRLachaertRLeopoldLDeBeuleKMcNeeleyDHoetelmansR. 2007. The effect of CYP3A4 inhibition on the clinical pharmacokinetics of TMC207. abstr PS-71358\u201311. Proc. 38th World Conf. Lung Health, Cape Town, South Africa."},{"key":"e_1_3_3_40_2","volume-title":"Proc. 38th World Conf. Lung Health","author":"Mesens N","year":"2007","unstructured":"MesensNVerbeeckJRouanM. 2007. Elucidating the role of M2 in the preclinical safety profile of TMC207, abstr PS-71291\u201311. Proc. 38th World Conf. Lung Health, Cape Town, South Africa."}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.03246-14","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.03246-14","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,4]],"date-time":"2025-05-04T04:25:32Z","timestamp":1746332732000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.03246-14"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,11]]},"references-count":39,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2014,11]]}},"alternative-id":["10.1128\/AAC.03246-14"],"URL":"https:\/\/doi.org\/10.1128\/aac.03246-14","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,11]]},"assertion":[{"value":"2014-05-06","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2014-08-07","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2014-10-16","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}